COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies

Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic malignancies, with a reported risk of death of 34% (Vijenthira et al, 2020). The ASH-ASTCT COVID-19 vaccine guidelines indicate that certain immunocompromised patient populations could have an attenuated response...

Descripción completa

Detalles Bibliográficos
Autores principales: Goksu, Suleyman Y, Rolwes, John, Premnath, Naveen, Patel, Prapti, Ikpefan, Ruth, Kaur, Gurbakhash, Vusirikala, Madhuri, Bat, Taha, Chen, Weina, Ramakrishnan, Praveen, Kansagra, Ankit, Anderson, Larry D., Awan, Farrukh T., Collins, Robert H., Chung, Stephen, Madanat, Yazan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
906.Outcomes Research-Myeloid Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701603/
http://dx.doi.org/10.1182/blood-2021-152930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701603/
http://dx.doi.org/10.1182/blood-2021-152930

Ejemplares similares